How can Secure My Meds work for you?

Support and savings at your fingertips

The Secure My Meds program was created to help you get your medication in a timely manner. As a member of the program, you will have access to a range of services to support you.

Welcome call

Your doctor’s office can help you enroll in the Secure My Meds program or you can enroll yourself by calling 1-888-884-2655. After this step has been completed, you will receive a welcome call to confirm your enrollment in the program.

Benefits support

A Secure My Meds representative will review your benefits coverage and inform you of any copay out-of-pocket costs. If your insurance requires a prior authorization for your Xtampza ER prescription, your doctor’s office will be sent a prior authorization form.

Financial assistance

If you have commercial insurance, you may be eligible for the Xtampza ER Co-pay Assistance Program, which allows you to pay $0 for your first 30-day fill of Xtampza ER and as little as $25 for each additional 30 day fill.

Ask your doctor for the Xtampza ER Co-pay Card today, or download it here.

This offer is valid for commercially insured patients only. Maximum savings limit applies; patient out-of-pocket expense may vary. See Program Terms, Conditions, and Eligibility Criteria.

Pharmacy finder service

A Secure My Meds representative will contact you to:

1) ask if you have a preferred pharmacy; and

2) let you know if Xtampza ER is available at your preferred pharmacy

  • If Xtampza ER is not available at your preferred pharmacy, a representative can assist you in finding a pharmacy in the Secure My Meds network where Xtampza ER is available
  • If your preferred pharmacy is not in the Secure My Meds network, a participating pharmacy can be recommended.

    Note: you can still choose to fill your Xtampza ER prescription at a pharmacy that is not in-network

  • Home delivery option: You may also choose to have Xtampza ER delivered to your home through a specialty pharmacy in the Secure My Meds network

If you have any questions, call 1-888-884-2655 to reach a representative who can walk you through the process.

Get support with Secure My Meds today. Ask your doctor for more information or enroll by calling 1-888-884-2655

INDICATIONS AND USAGE

Xtampza® ER (oxycodone) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Limitations of Use

  • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Xtampza ER for use in patients for whom alternative treatment options (eg, non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain
  • Xtampza ER is not indicated as an as-needed (prn) analgesic

IMPORTANT SAFETY INFORMATION

WARNING: ADDICTION, ABUSE, and MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

Addiction, Abuse, and Misuse

Xtampza ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of these behaviors or conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of Xtampza ER. Monitor for respiratory depression, especially during initiation of Xtampza ER or following a dose increase.

Accidental Ingestion

Accidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of oxycodone.

Neonatal Opioid Withdrawal Syndrome

Prolonged use of Xtampza ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Cytochrome P450 3A4 Interaction

The concomitant use of Xtampza ER with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving Xtampza ER and any CYP3A4 inhibitor or inducer.

Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

  • Reserve concomitant prescribing of Xtampza ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
  • Limit dosages and durations to the minimum required.
  • Follow patients for signs and symptoms of respiratory depression and sedation.

CONTRAINDICATIONS:

WARNINGS AND PRECAUTIONS:

Addiction, Abuse, and Misuse

Life-Threatening Respiratory Depression

Neonatal Opioid Withdrawal Syndrome

Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers

Risks From Concomitant Use With Benzodiazepines or Other CNS Depressants

Risk of Life-threatening Respiratory Depression in Patients With Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients

The use of Xtampza ER in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients With Chronic Pulmonary Disease:

Xtampza ER-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Xtampza ER.

Elderly, Cachectic, or Debilitated Patients:

Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients.

Monitor such patients closely, particularly when initiating and titrating Xtampza ER and when Xtampza ER is given concomitantly with other drugs that depress respiration.

Alternatively, consider the use of non-opioid analgesics in these patients. Use an alternative analgesic for patients who require a dose of Xtampza ER less than 9 mg.

Adrenal Insufficiency

Severe Hypotension

Risks of Use in Patients With Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness

Risks of Use in Patients With Gastrointestinal Conditions

Risk of Use in Patients With Seizure Disorders

Withdrawal

Risks of Driving and Operating Machinery

Laboratory Monitoring

ADMINISTRATION WITH FOOD:

ADVERSE REACTIONS:

Please see full Prescribing Information, including Boxed Warning and Medication Guide.